PreppinPeppers › Facts › Lab article
Tirzepatide: Reference Overview and Reconstitution Notes
Machine-readable facts for this Lab article. The full page is https://www.preppinpeppers.com/blogs/the-lab/tirzepatide.
TL;DR
Tirzepatide is a 39-amino-acid lab-made peptide that activates both the GIP and GLP-1 receptors, a dual agonist. Research reference and handling notes.
Facts Index
| Fact ID | Category | Entity | Attribute | Value | Source |
|---|---|---|---|---|---|
| tirzepatide:title | identity | Tirzepatide: Reference Overview and Reconstitution Notes | title | Tirzepatide: Reference Overview and Reconstitution Notes | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:published | identity | Tirzepatide: Reference Overview and Reconstitution Notes | published | 2026-07-10 | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:author | identity | Tirzepatide: Reference Overview and Reconstitution Notes | author | Preppin' Peppers Editorial Team | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:topics | identity | Tirzepatide: Reference Overview and Reconstitution Notes | topics | FDA-approved or specific-use, research | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:summary | content | Tirzepatide: Reference Overview and Reconstitution Notes | summary | Tirzepatide is a 39-amino-acid lab-made peptide that activates both the GIP and GLP-1 receptors, a dual agonist. Research reference and handling notes. | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-1 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | What it is | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-2 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | What it is | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-3 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | Research context and categorization | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-4 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | Status | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-5 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | Reconstitution notes (general) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-6 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | Dilution and handling notes (compound-specific) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-7 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | Handling and storage | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-8 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | Related reading | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-9 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | Tools and supplies | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:section-11 | content | Tirzepatide: Reference Overview and Reconstitution Notes | section | What the research community gets wrong about tirzepatide | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:source-dailymed-nlm-nih-gov | source | Tirzepatide: Reference Overview and Reconstitution Notes | cites | View the DailyMed entry - dailymed.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:product-gansulin-metal-peptide-pen | products | Tirzepatide: Reference Overview and Reconstitution Notes | references product | Gansulin Pen · Reusable Click-Dial, 3 ml (1-60 Units) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:product-gansulin-3ml-cartridge | products | Tirzepatide: Reference Overview and Reconstitution Notes | references product | Gansulin-Compatible 3 ml Glass Cartridge for Pens (10-Pack) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:source-pubchem-ncbi-nlm-nih-gov | source | Tirzepatide: Reference Overview and Reconstitution Notes | cites | NCBI PubChem CID 156588324: Tirzepatide (C225H348N48O68) - pubchem.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:source-dailymed-nlm-nih-gov-2 | source | Tirzepatide: Reference Overview and Reconstitution Notes | cites | FDA/DailyMed , Mounjaro (tirzepatide) prescribing information: dual GIP and GLP-1 receptor agonist with a C20 fatty diacid for albumin binding - dailymed.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:source-pmc-ncbi-nlm-nih-gov | source | Tirzepatide: Reference Overview and Reconstitution Notes | cites | Nauck and D'Alessio, Cardiovasc Diabetol 2022: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - pmc.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:source-pubmed-ncbi-nlm-nih-gov | source | Tirzepatide: Reference Overview and Reconstitution Notes | cites | Jastreboff et al., N Engl J Med 2022: Tirzepatide Once Weekly for the Treatment of Obesity - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:source-pubmed-ncbi-nlm-nih-gov-2 | source | Tirzepatide: Reference Overview and Reconstitution Notes | cites | Sumithran et al., J Endocrinol 2025: Cardiovascular effects of tirzepatide - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
| tirzepatide:source-www-uniprot-org | source | Tirzepatide: Reference Overview and Reconstitution Notes | cites | UniProtKB/Swiss-Prot P43220: Glucagon-like peptide 1 receptor (GLP1R, Homo sapiens), UniProt release 2026-03 - www.uniprot.org | Lab article (https://www.preppinpeppers.com/blogs/the-lab/tirzepatide) (evidence) |
FAQ
- What type of peptide is tirzepatide and how does it work mechanistically?
- Tirzepatide is a synthetic 39-amino-acid peptide that simultaneously activates both the GIP receptor and the GLP-1 receptor—two incretin-system receptors linked to blood sugar regulation and metabolic signaling.
- What is tirzepatide's regulatory classification and WADA status as of 2026?
- It is marketed under the brand names Mounjaro (type 2 diabetes, since 2022) and Zepbound (weight management, since 2023; a sleep apnea indication added later) in jurisdictions that have authorized those specific pharmaceutical products. It is not approved by any regulator for the research use described here, and this material is for research, educational and demonstration purposes only — not a licensed product for human or veterinary use. As of the 2026 WADA cycle it sits on the Monitoring Program, not the prohibited list, though the class is under active review.
- How is tirzepatide lyophilized powder reconstituted for laboratory use?
- Add bacteriostatic water to the vial; concentration (mg/mL) equals total mg of powder divided by mL of solvent added. A 10 mg vial plus 1 mL yields 10 mg/mL. Use a peptide calculator to plan volumes for other vial sizes.